Hrt Financial LP Viking Therapeutics, Inc. Transaction History

Hrt Financial LP

  • $18.1 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
BUY
$47.39 - $80.2 $18.8 Million - $31.8 Million
396,583 New
396,583 $21 Million
Q4 2023

Feb 09, 2024
BUY
$9.24 - $19.64 $1.15 Million - $2.45 Million
124,971 New
124,971 $2.33 Million
Q1 2023

May 12, 2023
SELL
$8.08 - $17.33 $875,152 - $1.88 Million
-108,311 Reduced 28.54%
271,255 $4.52 Million
Q4 2022

Feb 10, 2023
BUY
$2.72 - $9.4 $1.03 Million - $3.57 Million
379,566 New
379,566 $3.57 Million
Q2 2022

Aug 12, 2022
SELL
$2.11 - $3.15 $122,169 - $182,385
-57,900 Reduced 24.74%
176,166 $509,000
Q1 2022

May 16, 2022
BUY
$3.0 - $4.88 $369,324 - $600,767
123,108 Added 110.95%
234,066 $702,000
Q4 2021

Feb 14, 2022
BUY
$4.6 - $6.72 $184,933 - $270,164
40,203 Added 56.82%
110,958 $510,000
Q3 2021

Nov 15, 2021
BUY
$5.58 - $7.04 $280,512 - $353,907
50,271 Added 245.42%
70,755 $444,000
Q2 2021

Aug 16, 2021
BUY
$5.19 - $6.73 $106,311 - $137,857
20,484 New
20,484 $122,000
Q1 2021

May 17, 2021
SELL
$5.74 - $9.67 $96,437 - $162,465
-16,801 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$5.3 - $6.71 $89,045 - $112,734
16,801 New
16,801 $94,000
Q1 2019

May 14, 2019
SELL
$7.58 - $9.94 $345,882 - $453,572
-45,631 Closed
0 $0
Q4 2018

Feb 15, 2019
BUY
$7.16 - $16.21 $326,717 - $739,678
45,631 New
45,631 $349,000

Others Institutions Holding VKTX

# of Institutions
473
Shares Held
66.2M
Call Options Held
5.72M
Put Options Held
3.39M
View Full List

About Viking Therapeutics, Inc.

VKTX Quotes by TradingView
  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email